Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice
Adama Kamagate, … , Marcia Meseck, H. Henry Dong
Adama Kamagate, … , Marcia Meseck, H. Henry Dong
Published May 22, 2008
Citation Information: J Clin Invest. 2008;118(6):2347-2364. https://doi.org/10.1172/JCI32914.
View: Text | PDF
Research Article

FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice

  • Text
  • PDF
Abstract

Excessive production of triglyceride-rich VLDL is attributable to hypertriglyceridemia. VLDL production is facilitated by microsomal triglyceride transfer protein (MTP) in a rate-limiting step that is regulated by insulin. To characterize the underlying mechanism, we studied hepatic MTP regulation by forkhead box O1 (FoxO1), a transcription factor that plays a key role in hepatic insulin signaling. In HepG2 cells, MTP expression was induced by FoxO1 and inhibited by exposure to insulin. This effect correlated with the ability of FoxO1 to bind and stimulate MTP promoter activity. Deletion or mutation of the FoxO1 target site within the MTP promoter disabled FoxO1 binding and resulted in abolition of insulin-dependent regulation of MTP expression. We generated mice that expressed a constitutively active FoxO1 transgene and found that increased FoxO1 activity was associated with enhanced MTP expression, augmented VLDL production, and elevated plasma triglyceride levels. In contrast, RNAi-mediated silencing of hepatic FoxO1 was associated with reduced MTP and VLDL production in adult mice. Furthermore, we found that hepatic FoxO1 abundance and MTP production were increased in mice with abnormal triglyceride metabolism. These data suggest that FoxO1 mediates insulin regulation of MTP production and that augmented MTP levels may be a causative factor for VLDL overproduction and hypertriglyceridemia in diabetes.

Authors

Adama Kamagate, Shen Qu, German Perdomo, Dongming Su, Dae Hyun Kim, Sandra Slusher, Marcia Meseck, H. Henry Dong

×

Figure 4

VLDL production in FoxO1S253A transgenic versus control mice.

Options: View larger image (or click on image) Download as PowerPoint
VLDL production in FoxO1S253A transgenic versus control mice.
   
Male F...
Male FoxO1S253A transgenic mice (n = 6) and control littermates (n = 6) at 6 months of age were fasted for 5 h, followed by intravenous injection of tyloxapol at 500 mg/kg body weight per mouse to inhibit plasma VLDL clearance. (A) Aliquots of tail vein blood were taken at different times for the determination of plasma TG levels. (B) The relative rates of VLDL secretion are defined by the slopes of linear increases of plasma TG as a function of time following intravenous injection of tyloxapol. (C) Aliquots of plasma (20 μg protein) obtained from mice at 80 min after tyloxapol injection were analyzed by semiquantitative immunoblot assay using anti-apoB antibody for the determination of plasma apoB secretion. Mice were sacrificed at 6 months of age, and liver tissues were subjected to semiquantitative immunoblot analysis for the determination of hepatic MTP protein abundance (D), and separately to real-time quantitative RT-PCR for the determination of hepatic MTTP mRNA levels (E). *P < 0.05 versus control. In addition, liver tissues were subjected to ChIP analysis using preimmune rabbit serum (lanes 1 and 2) and rabbit anti-FoxO1 antibody (lanes 3 and 4). The resulting immunoprecipitates were analyzed by PCR (F) and immunoblot (G) assays as described in Figure 3.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts